Search results for: HTA

OHE in the Spotlight: Summer 2011

22 September 2011

…and participation in a discussion session at the HTAi Annual Meeting.  One poster focused on the evolution of HTA in Brazil and the other on understanding the evolution of HTA…

Value, Affordability, and Decision Making

…in HTAs: Argentina – Long Road to Institutionalizing HTA In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés…

Around The World in HTAs: The Netherlands – 5 Routes for New Tech

24 May 2023

…use, efficient procurement, and management of the insurance package. Next steps for the Dutch HTA The Dutch government aspires to broaden the systematic application of full HTA towards other types…

Around The World in HTAs: Spain – Are We There Yet?

15 March 2023

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Laura Vallejo-Torres, University of Las Palmas de Gran Canaria, and…

Workshop on HTA and Regulatory Review

13 May 2010

…issues raised.  Representatives of HTA bodies, regulatory agencies, the pharmaceutical industry and academics participated. The basic problem identified in the workshop is that the remits and requirements of regulatory authorities and HTA agencies…

HTAinSite: The NICE Decision Database

18 May 2010

…making and evidence has become a formidable, time intensive task. HTAinSite offers a way round that. Updated regularly, HTAinSite contains information for all NICE TAs. The service allows subscribers to: quickly…

Are Recommendations for HTA of Gene Therapies Being Achieved?

11 September 2023

…recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada. Key takeaways Changes to HTA methodologies and evidence generation aimed…

Setting the Right Discount Rate for HTA in the Slovak Republic

21 May 2023

…determine whether differential discounting is appropriate. Increase transparency around the choice of discounting method and rate(s) for use in HTA. HTA agencies’ choice of discounting method and rate(s) should be…

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

8 December 2022

…and discussed actionable recommendations resulting from an expert roundtable. The report identified four broad categories of challenges faced by gene therapies undergoing health technology assessment (HTA): initial assessment of clinical…